AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

GKOS · NYSE · Medical - Devices

Glaukos (GKOS)

Develops implantable glaucoma therapies and corneal cross-linking treatments.

$162.16

vs last close+0.63 (+0.39%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	78	82	86	96	97	105	107	124	134	143	151	186
Cost of revenue	19	19	20	23	23	29	24	27	29	32	33	34
Gross profit	60	63	65	73	74	77	82	97	105	111	117	152
	88	102	104	103	99	106	103	120	121	138	137	169
Research & development	33	37	31	34	35	37	32	37	38	44	44	51
Selling, general & administrative	54	63	62	66	64	69	71	83	83	95	93	116
Other expenses	0	2	12	3	0	0	0	0	0	0	0	2
Operating income	−28	−39	−39	−30	−25	−29	−21	−23	−16	−27	−20	−17
	−2	2	−1	−20	3	−5	3	3	0	−113	1	0
Interest income	3	3	3	3	3	2	3	3	3	3	2	2
Interest expense	3	3	3	3	2	2	1	1	1	1	1	1
Other non-operating income	−1	−5	−2	17	−5	3	−4	−4	−2	112	−2	−2
Income before tax	−30	−37	−40	−50	−21	−34	−18	−19	−16	−140	−19	−18
Income tax expense	0	0	0	0	0	0	0	0	0	−6	0	1
Net income from continuing operations	−30	−37	−41	−51	−21	−34	−18	−20	−16	−134	−20	−18
Net income	−30	−37	−41	−51	−21	−34	−18	−20	−16	−134	−20	−18
EPS, basic	−$0.63	−$0.75	−$0.82	−$1.06	−$0.39	−$0.60	−$0.32	−$0.34	−$0.28	−$2.32	−$0.34	−$0.31
EPS, diluted	−$0.63	−$0.75	−$0.82	−$1.06	−$0.39	−$0.60	−$0.32	−$0.34	−$0.28	−$2.32	−$0.34	−$0.31
Weighted average shares, basic	49	49	50	51	55	56	57	57	57	58	58	58
Weighted average shares, diluted	49	49	50	51	55	56	57	57	57	58	58	58
EBITDA	−15	−24	−27	−37	−10	−22	−7	−9	−5	−125	−5	−7
Depreciation & amortization	12	10	10	10	10	10	9	10	10	13	13	9
EBIT	−27	−33	−37	−47	−20	−32	−17	−18	−15	−139	−18	−16